43CLINICAL STUDIES NON-RANDOMIZED OBSERVATIONAL STUDIES
Results The principal symptom (most commonly pain, then inflammation) had resolved
completely at the end of therapy in 41 patients (59.4%) in the Traumeel® group vs. 37 patients (57.8%) in the conventional group (Figure 17).
Most patients showed improvement in the principal symptom within 4 days: 49 (71%) in the Traumeel® group and 31 (48%) in the conventional treatment group.
Cox s proportional hazard regression analysis of the time until improvement shows a greater benefit with Traumeel®: unadjusted hazard ratio 0.95 (95% CI 0.67 1.37), adjusted (for diagnosis, symptoms, age, etc.) hazard ratio 0.94 (95% CI 0.56 1.37). or complications.
Treatment compliance was judged to be good in both groups, but appeared to better in patients receiving Traumeel®: compliance reported as very good in 72% of Traumeel® patients compared with 49% of conventionally treated patients.
Conclusions Traumeel® is as effective as conventional medicines in the management of mild to
moderate injuries/trauma. This study contributes to the evidence for the broad clinical effectiveness of
Traumeel® in the treatment of acute injuries and trauma.
Figure 17 Changes in the principal symptoms of pain and inflammation at the end of the treatment period.
Pe rc
en ta
ge o
f p at
ie nt
s
Traumeel® ointment N = 69
Conventional N = 64
100
90
80
70
60
50
40
30
20
10
0 Pain
symptoms improved
15
39
Pain symptoms
cured
78
61
32
Inflammatory symptoms
cured
48
Pain symptoms unchanged
8 0
Inflammatory symptoms unchanged
0 4
Inflammatory symptoms improved
68
48
